See more : Swire Properties Limited (1972.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Vector Group Ltd. (VGR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vector Group Ltd., a leading company in the Tobacco industry within the Consumer Defensive sector.
You may be interested
- Bermaz Auto Berhad (5248.KL) Income Statement Analysis – Financial Results
- Questor Technology Inc. (QUTIF) Income Statement Analysis – Financial Results
- MeaTech 3D Ltd. (MITC) Income Statement Analysis – Financial Results
- PT Bank Mega Tbk (MEGA.JK) Income Statement Analysis – Financial Results
- Sirio Pharma Co., Ltd. (300791.SZ) Income Statement Analysis – Financial Results
Vector Group Ltd. (VGR)
About Vector Group Ltd.
Vector Group Ltd., through its subsidiaries, manufactures and sells cigarettes in the United States. It operates in two segments, Tobacco and Real Estate. The company produces cigarettes in 100 combinations under the EAGLE 20's, Pyramid, Montego, Grand Prix, Liggett Select, Eve, and USA brand names, as well as various partner and private label brands. It markets and sells its cigarettes to wholesalers and distributors of tobacco and convenience products, as well as grocery, drug, and convenience store chains. The company also engages in real estate investment business. The company was formerly known as Brooke Group Ltd. and changed its name to Vector Group Ltd. in May 2000. Vector Group Ltd. was founded in 1873 and is headquartered in Miami, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.42B | 1.44B | 1.22B | 1.23B | 1.12B | 1.87B | 1.81B | 1.69B | 1.66B | 1.59B | 1.08B | 1.10B | 1.13B | 1.06B | 801.49M | 565.19M | 555.43M | 506.25M | 478.43M | 323.19M | 334.04M | 310.41M | 296.21M | 533.35M | 459.50M | 362.00M | 301.90M | 348.20M | 338.00M | 347.50M | 673.50M | 720.10M | 1.17B | 1.10B | 572.90M | 501.00M | 531.90M |
| Cost of Revenue | 965.35M | 998.66M | 769.54M | 819.60M | 774.89M | 1.29B | 1.23B | 1.10B | 1.11B | 1.10B | 767.03M | 832.33M | 892.88M | 845.11M | 577.39M | 335.30M | 337.08M | 315.16M | 285.39M | 149.99M | 144.28M | 151.96M | 108.53M | 140.55M | 123.17M | 109.80M | 106.30M | 122.30M | 83.70M | 91.10M | 318.70M | 361.60M | 687.70M | 588.60M | 299.70M | 245.50M | 287.30M |
| Gross Profit | 458.92M | 442.35M | 451.16M | 409.08M | 344.72M | 577.78M | 579.43M | 593.61M | 547.47M | 494.26M | 312.89M | 263.21M | 240.50M | 218.18M | 224.11M | 229.89M | 218.35M | 191.09M | 193.03M | 173.20M | 189.77M | 158.46M | 187.68M | 392.81M | 336.33M | 252.20M | 195.60M | 225.90M | 254.30M | 256.40M | 354.80M | 358.50M | 482.70M | 510.10M | 273.20M | 255.50M | 244.60M |
| Gross Profit Ratio | 32.22% | 30.70% | 36.96% | 33.29% | 30.79% | 30.89% | 32.06% | 35.10% | 33.04% | 31.06% | 28.97% | 24.03% | 21.22% | 20.52% | 27.96% | 40.67% | 39.31% | 37.75% | 40.35% | 53.59% | 56.81% | 51.05% | 63.36% | 73.65% | 73.20% | 69.67% | 64.79% | 64.88% | 75.24% | 73.78% | 52.68% | 49.78% | 41.24% | 46.43% | 47.69% | 51.00% | 45.99% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 117.05M | 98.35M | 126.95M | 112.50M | 105.36M | 328.42M | 314.07M | 312.83M | 289.47M | 249.31M | 101.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 5.23M | 4.75M | 4.46M | 4.10M | 3.75M | 27.10M | 23.12M | 26.23M | 30.75M | 30.03M | 11.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 122.27M | 103.10M | 131.42M | 116.60M | 109.11M | 355.51M | 337.19M | 339.06M | 320.22M | 279.34M | 113.60M | 108.27M | 97.18M | 90.71M | 85.04M | 94.58M | 92.97M | 90.83M | 116.80M | 144.05M | 167.98M | 173.89M | 156.33M | 353.64M | 266.87M | 186.90M | 162.90M | 221.00M | 237.20M | 235.40M | 312.80M | 354.20M | 514.90M | 472.30M | 215.00M | 202.20M | 182.50M |
| Other Expenses | 34.00K | -547.00K | -617.00K | -3.26M | -1.95M | -1.02M | -2.33M | -1.78M | 100.00K | 1.26M | 3.00K | -148.00K | 1.00K | 1.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 122.27M | 103.10M | 131.42M | 116.60M | 109.11M | 355.51M | 337.19M | 339.06M | 320.22M | 279.34M | 113.60M | 108.27M | 97.18M | 90.71M | 85.04M | 94.58M | 92.97M | 88.62M | 104.05M | 144.05M | 167.98M | 173.89M | 156.33M | 352.71M | 265.82M | 195.50M | 171.00M | 229.80M | 246.30M | 242.20M | 331.80M | 364.40M | 555.60M | 506.60M | 220.50M | 206.90M | 187.10M |
| Cost & Expenses | 1.09B | 1.10B | 900.96M | 936.20M | 884.00M | 1.65B | 1.57B | 1.44B | 1.43B | 1.38B | 880.63M | 940.60M | 990.06M | 935.82M | 662.43M | 429.88M | 430.05M | 403.79M | 389.44M | 294.04M | 312.25M | 325.85M | 264.87M | 493.25M | 388.98M | 305.30M | 277.30M | 352.10M | 330.00M | 333.30M | 650.50M | 726.00M | 1.24B | 1.10B | 520.20M | 452.40M | 474.40M |
| Interest Income | 23.49M | 8.63M | 1.92M | 5.62M | 11.09M | 11.35M | 7.39M | 6.02M | 7.04M | 5.80M | 4.38M | 2.39M | 1.04M | 0.00 | 492.00K | 5.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 108.62M | 110.67M | 112.73M | 121.28M | 137.54M | 203.78M | 173.69M | 142.98M | 120.69M | 166.20M | 144.56M | 125.06M | 101.92M | 84.10M | 68.49M | 62.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.35M | 10.60M | 38.28M | 38.13M | 45.47M | 18.31M | 18.35M | 22.24M | 25.65M | 24.50M | 12.63M | 10.61M | 10.61M | 10.79M | 10.40M | 10.06M | 10.20M | 9.89M | 11.22M | 11.82M | 14.73M | 13.81M | 9.97M | 12.65M | 7.70M | 8.60M | 8.10M | 8.80M | 9.10M | 6.80M | 19.00M | 10.20M | 40.70M | 34.30M | 5.50M | 4.70M | 4.60M |
| EBITDA | 347.00M | 338.45M | 339.02M | 319.95M | 251.84M | 302.15M | 281.47M | 283.59M | 254.05M | 272.97M | 217.91M | 189.39M | 235.69M | 180.46M | 164.68M | 166.96M | 114.75M | 124.44M | 73.71M | 51.28M | 57.09M | -1.62M | 34.26M | -197.44M | -215.45M | 78.90M | 46.30M | 4.90M | 12.70M | 21.70M | 7.20M | 4.30M | -32.20M | -418.70M | 59.60M | 48.70M | 62.00M |
| EBITDA Ratio | 24.36% | 23.84% | 28.70% | 26.37% | 22.49% | 14.38% | 15.85% | 16.77% | 15.65% | 15.94% | 22.44% | 17.92% | 15.36% | 15.54% | 20.55% | 31.07% | 20.66% | 24.58% | 15.41% | 15.87% | 17.09% | 4.38% | 11.57% | -37.02% | -46.89% | 21.80% | 15.34% | 1.32% | 3.76% | 6.24% | 1.07% | -5.19% | -2.98% | -38.11% | 10.40% | 9.72% | 11.66% |
| Operating Income | 336.65M | 339.01M | 320.44M | 294.43M | 234.62M | 224.05M | 235.65M | 234.51M | 199.92M | 212.44M | 111.19M | 154.93M | 143.32M | 111.31M | 154.28M | 165.57M | 104.54M | 114.55M | 62.49M | 39.45M | 42.36M | -201.00K | 24.29M | -210.09M | -223.15M | 70.30M | 38.20M | -4.20M | 3.60M | 14.90M | -11.80M | -47.60M | -75.60M | -453.00M | 54.10M | 44.00M | 57.40M |
| Operating Income Ratio | 23.64% | 23.53% | 26.25% | 23.96% | 20.96% | 11.98% | 13.04% | 13.87% | 12.06% | 13.35% | 10.30% | 14.14% | 12.65% | 10.47% | 19.25% | 29.29% | 18.82% | 22.63% | 13.06% | 12.21% | 12.68% | -0.06% | 8.20% | -39.39% | -48.56% | 19.42% | 12.65% | -1.21% | 1.07% | 4.29% | -1.75% | -6.61% | -6.46% | -41.23% | 9.44% | 8.78% | 10.79% |
| Total Other Income/Expenses | -88.20M | -118.45M | -110.48M | -113.39M | -114.67M | -144.49M | -157.33M | -133.22M | -92.22M | -130.16M | -50.47M | -101.22M | -20.16M | -25.74M | -110.53M | -40.73M | 1.10M | -33.99M | -3.34M | -23.04M | -41.56M | -32.34M | 11.93M | 459.63M | 541.18M | -92.10M | -74.90M | -60.20M | -53.00M | -56.70M | -24.90M | -18.30M | -57.90M | 850.60M | -7.30M | -1.80M | -8.40M |
| Income Before Tax | 248.45M | 220.56M | 209.96M | 181.04M | 125.02M | 79.56M | 89.17M | 126.43M | 107.71M | 82.28M | 60.72M | 53.72M | 123.16M | 85.57M | 28.54M | 94.57M | 126.60M | 68.48M | 85.77M | 6.11M | -19.77M | -47.77M | 36.22M | 249.54M | 318.03M | -35.40M | -50.30M | -64.10M | -45.00M | -42.50M | -1.90M | -24.20M | -130.80M | 397.60M | 45.40M | 46.80M | 49.10M |
| Income Before Tax Ratio | 17.44% | 15.31% | 17.20% | 14.73% | 11.17% | 4.25% | 4.93% | 7.48% | 6.50% | 5.17% | 5.62% | 4.90% | 10.87% | 8.05% | 3.56% | 16.73% | 22.79% | 13.53% | 17.93% | 1.89% | -5.92% | -15.39% | 12.23% | 46.79% | 69.21% | -9.78% | -16.66% | -18.41% | -13.31% | -12.23% | -0.28% | -3.36% | -11.18% | 36.19% | 7.92% | 9.34% | 9.23% |
| Income Tax Expense | 64.93M | 61.86M | 62.81M | 54.12M | 31.09M | 21.55M | -1.58M | 49.16M | 41.23M | 33.17M | 23.67M | 23.10M | 48.14M | 31.49M | 3.73M | 34.07M | 52.80M | 25.77M | 41.21M | -6.96M | -666.00K | -6.39M | 15.02M | 81.78M | 82.26M | -59.60M | 1.10M | 1.40M | 300.00K | -24.50M | 5.30M | 8.10M | 18.80M | 21.70M | 19.90M | 16.60M | 18.40M |
| Net Income | 183.53M | 158.70M | 219.46M | 92.94M | 100.97M | 58.11M | 84.57M | 71.13M | 59.20M | 36.86M | 37.30M | 30.62M | 75.02M | 54.08M | 24.81M | 60.50M | 73.80M | 42.71M | 53.47M | 6.73M | -15.61M | -31.79M | 20.66M | 174.22M | 235.67M | 27.40M | -49.90M | -62.50M | -33.90M | 110.10M | 106.80M | -75.80M | -149.60M | 375.90M | 25.50M | 30.20M | 30.70M |
| Net Income Ratio | 12.89% | 11.01% | 17.98% | 7.56% | 9.02% | 3.11% | 4.68% | 4.21% | 3.57% | 2.32% | 3.45% | 2.80% | 6.62% | 5.09% | 3.09% | 10.71% | 13.29% | 8.44% | 11.18% | 2.08% | -4.67% | -10.24% | 6.98% | 32.66% | 51.29% | 7.57% | -16.53% | -17.95% | -10.03% | 31.68% | 15.86% | -10.53% | -12.78% | 34.21% | 4.45% | 6.03% | 5.77% |
| EPS | 1.17 | 1.01 | 1.40 | 0.60 | 0.64 | 0.40 | 0.54 | 0.48 | 0.40 | 0.27 | 0.30 | 0.25 | 0.63 | 0.46 | 0.21 | 0.52 | 0.64 | 0.39 | 0.60 | 0.08 | -0.18 | -0.40 | 0.29 | 2.93 | 4.04 | 0.48 | -1.03 | -1.23 | -0.66 | 2.23 | 2.01 | -1.54 | -2.47 | 5.61 | 0.38 | 0.45 | 0.50 |
| EPS Diluted | 1.16 | 1.01 | 1.40 | 0.60 | 0.63 | 0.40 | 0.54 | 0.48 | 0.40 | 0.27 | 0.30 | 0.25 | 0.63 | 0.46 | 0.21 | 0.47 | 0.63 | 0.38 | 0.56 | 0.08 | -0.18 | -0.40 | 0.25 | 2.61 | 3.31 | 0.40 | -1.03 | -1.23 | -0.43 | 2.23 | 2.01 | -1.54 | -2.47 | 5.61 | 0.38 | 0.45 | 0.50 |
| Weighted Avg Shares Out | 153.20M | 152.75M | 152.40M | 150.22M | 146.63M | 146.36M | 145.99M | 147.03M | 146.85M | 134.84M | 122.63M | 123.11M | 116.24M | 118.17M | 113.23M | 110.29M | 107.06M | 102.31M | 87.57M | 80.55M | 84.57M | 80.03M | 71.59M | 59.47M | 58.35M | 56.90M | 48.26M | 50.76M | 50.99M | 49.26M | 53.24M | 49.09M | 60.52M | 8.88M | 67.20M | 66.99M | 61.44M |
| Weighted Avg Shares Out (Dil) | 153.33M | 152.89M | 152.47M | 150.25M | 147.37M | 146.48M | 146.27M | 149.71M | 146.85M | 134.84M | 122.95M | 123.11M | 116.54M | 118.17M | 113.34M | 121.65M | 110.05M | 105.00M | 103.41M | 86.30M | 84.57M | 80.03M | 81.05M | 66.70M | 71.14M | 69.08M | 48.26M | 50.76M | 79.15M | 49.26M | 53.24M | 49.09M | 60.52M | 8.88M | 67.20M | 66.99M | 61.44M |
Vector Group (VGR) Q2 Earnings and Revenues Surpass Estimates
Vector Group (VGR) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.32 per share a year ago.
4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial initiation is expected in Q1 2025. Results from...
Want $5,000? Invest $10,000 in These 7 Dividend Stocks
24/7 Wall Street Insights An anticipated interest rate cut by the Federal Reserve to help the troubled real estate market will likely hike inflation further.
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States
SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that use of the Company's...
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
ROCKVILLE, Md.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River's premier...
3 Overlooked Tobacco Stocks Quietly Making Investors Rich
Tobacco stocks have a bad reputation. Investors with a particular set of ethics tend to veer away from them because the companies' products are known to be detrimental to people's health.
Elastic Adds Vector Database and Broad Retrieval Capabilities to LangChain
SAN FRANCISCO--(BUSINESS WIRE)--Elastic (NYSE: ESTC), the Search AI Company, today announced a partner integration package with LangChain that will simplify the import of vector database and retrieval capabilities of Elasticsearch into LangChain applications. This deeper collaboration and native support will...
Nvidia Stock Could Rise 10-Fold On New $10 Billion Growth Vector
Nvidia stock has soared to about $1,200 a share — up some 287% since the chip designer's boffo May 2023 earnings report kindled generative AI fever.
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer frameworks. Based on decades of viral vector contract development and manufacturing organization (CDMO) experience, the Company...
Spicing Things Up: 3 Sin Stocks for the Adventurous Investor
In an age where environmental, social and governance ( ESG ) directives are consistently being pushed, the concept of sin stocks to buy might appear anachronistic. Nevertheless, those investors who want to indulge in certain enticing opportunities may be looking...
Source: https://incomestatements.info
Category: Stock Reports